ORLANDO, Fla., Dec. 7, 2010 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, today reported that epratuzumab, the Company's humanized anti-CD22 antibody, conjugated with SN-38, the active component of irinotecan, produced significant anti-tumor responses in a mouse model of human lymphoma. Furthermore, combining the antibody-drug conjugate (ADC) with veltuzumab, a second-generation humanized anti-CD20 antibody, enhanced its therapeutic activity without additional toxicity. Results from these preclinical studies were presented at the 52nd annual meeting of the American Society of Hematology.
